atp synthase

D-α-Hydroxyglutaric acid disodium [Disodium (R)-2-Hydroxyglutarate] is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with a Ki of 0.628 mM.

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).

Oligomycin A (MCH 32) is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1 FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

ATP synthase inhibitor3 (compound PT6) is an orally active inhibitor targeting the F-ATP synthase of Mycobacterium tuberculosis (IC50=0.788 μM). It effectively inhibits the growth of the Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro, depleting intracellular ATP levels at an IC50 of 30 μM.

Mtb ATP synthase-IN-1 (compound 6ab) is a potent inhibitor of Mycobacterium tuberculosis (Mtb) ATP synthase (MIC = 0.452-0.499 μg mL) [1] that can be used in anti-mycobacterium research, showing low cytotoxicity (Vero IC 50 > 64 μg mL) and acceptable oral bioavailability with good metabolic stability.

ATP Synthase Inhibitor 2, a compound targeting Pseudomonas aeruginosa (PA) ATP synthase with an IC50 of 10 μg mL, fully inhibits the ATP synthesis activity of PA at a concentration of 128 μg mL [1].

ATP Synthase Inhibitor 2 (Compound 22) TFA is a potent inhibitor of Pseudomonas aeruginosa ATP synthase with an IC50 value of 10 μg mL. It effectively halts ATP synthesis in Pseudomonas aeruginosa at a concentration of 128 μg mL [1].

α-Hydroxyglutaric Acid Lithium, converted from glutamate in microorganisms and animals, is an inhibitor of α-ketoglutarate-dependent dioxygenase and 5-methylcytosine hydroxylase, and has an inhibitory effect on ATP synthase and mTOR signaling.

Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines.

Tideglusib (NP031112), a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3), is with anti-inflammatory and neuroprotective activities.

Trans-Aconitic acid is normally present in normal human urine, and it has been suggested that is present in larger amounts with Reye's syndrome and organic aciduria. trans-Aconitic acid is a substrate of enzyme trans-aconitate 2-methyltransferase (EC 2.1.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family.

Oligomycin B, an antibiotic isolated from marine Streptomyces, serves as an eukaryotic ATP synthase inhibitor and induces apoptosis.

9-ING-41 is a glycogen synthase kinase-3 inhibitor.

Gboxin is an inhibitor of oxidative phosphorylation that targets glioblastoma,inhibits the activity of F0F1 ATP synthase, with antitumour activity.

Tetradifon is a broad-spectrum organochlorine acaricide insecticide and a potent inhibitor of the mitochondrial oligomycin sensitivity conferring protein (OSCP)，a subunit of ATP synthase. Tetradifon is utilized for controlling a variety of mite pests and inhibiting energy-related mitochondrial activities including ADP-stimulated respiration and ATPase activity with an IC50 range of 4.5-27 nmoL/mg mitochondrial protein; it exerts oligomycin-like effects by inhibiting oxidative phosphorylation, inducing significant oxidative stress, and interfering with bone metabolism, making it a compound of interest for researching mitochondrial function, bone remodeling mechanisms, and nephrotoxicity.

mPTP-IN-1 (Compound 14e) is an inhibitor of the mitochondrial permeability transition pore (mPTP). By targeting the C subunit of ATP synthase, mPTP-IN-1 prevents calcium-induced opening of the mPTP. This compound is applicable in studies related to myocardial ischemia/reperfusion injury (IRI).

GSK3i XIII (GSK3 inhibitor XIII) is a GSK-3 ATP-binding site inhibitor.

SAR502250 is a potent, selective, ATP-competitive, orally active, and brain-penetrant GSK3 inhibitor with a human GSK-3β IC50 value of 12 nM, exhibiting antidepressant-like activity and being researched for potential application in Alzheimer's disease (AD) treatment.

Isoapoptolidin is a stable derivative of apoptolidin that demonstrates 10-fold reduced F1FO-ATP synthase inhibitory activity compared to apoptolidin (IC50s = 17 and 0.7 μM, respectively).

6-Me-ATP (N6-Methyl-ATP), a N6-modified adenosine triphosphate (ATP) derivative, exhibits strong binding affinity for glycogen synthase kinase 3 (GSK3) and serves as the phosphate donor in GSK3β-catalyzed phosphorylation of its substrate peptide [1].

GaMF1.39 is an antimycobacterial compound that targets the F-ATP synthase subunit γ, exhibiting enhanced anti-tuberculosis activity when used in combination with ETC inhibitors [1].